Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research
关键的科学成果推进了联合神经科学项目，并为进一步研究赚取了2500万美元的付款。
Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.
Evotec SE宣布在与Bristol Myers Squibb的战略合作中取得进展，进一步增强了先进神经科学项目的联合管道。Evotec收到2500万美元的付款以推进进一步研究。
Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression. The progress announced here leverages Evotec's PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.
Evotec和百时美施贵宝于2016年12月开始战略性神经科学合作，旨在为广泛的神经退行性疾病鉴定疾病修饰治疗方法，因为在该领域尚缺少能够减缓或逆转疾病进展的治疗方法。此次宣布的进展利用了Evotec的PanOmics平台和患者衍生的疾病模型，这是业内规模最大、技术最尖端的平台之一。